

First quarter 2021 Financial report



Progress beyond

Inside / regulated information

Published on May 5, 2021, at 7:00 a.m.

Forenote

Besides IFRS accounts, Solvay also presents alternative performance indicators to provide a more consistent and comparable indication of the Group's underlying financial performance and financial position, as well as cash flows. These indicators provide a balanced view of the Group's operations and are considered useful to investors, analysts and credit rating agencies as these measures provide relevant information on the Group's past or future performance, position or cash flows. These indicators are generally used in the sector it operates in and therefore serve as a useful aid for investors to compare the Group's performance with its peers. The underlying performance indicators adjust IFRS figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds, classified as equity under IFRS but treated as debt in the underlying statements, for impairments and for other elements that would distort the analysis of the Group's underlying performance. The comments on the results made on pages 3 to 8 are on an underlying basis, unless otherwise stated.

Underlying business review

Highlights

- **Net Sales** in the first quarter of 2021 were up 1.9% organically driven by strong demand in automotive, with organic sales in Specialty Polymers up 10% year-on-year, exceptional performance in Coatis up 55%, and recovery in the mining industry driving Technology Solutions sales up 15%, whereas sales in composites were 37% lower.
- Net Sales grew 8.6% organically year on year excluding Composites and Oil & Gas, which still face challenges yet have shown sequential improvement versus the fourth quarter.
- Structural **cost savings** of €80 million achieved in Q1, up 78% versus Q4 2020.
- Underlying EBITDA in Q1 2020 was up 10.3% organically yoy, and 7% higher than Q1 2019 on comparable FX & scope basis despite 3% lower sales, reflecting the impacts of significant cost reduction measures taken in the last 2 years. The **underlying EBITDA margin** increased yoy to a new record at 24.6% driven mainly by strong volume recovery in most markets and cost reductions measures, despite the adverse impacts such as increasing raw material and logistic prices as well as supply chain disruptions due to US storms and the Suez Canal blockage. This is 1.6 and 2.4 percentage points higher than Q1 2020 and Q1 2019, respectively.
- Underlying Net Profit was €240 million in Q1 2021, up 1.8% compared to Q1 2020.
- Free Cash Flow in Q1 2021 amounted to €282 million, up 40% of Q1 2020, reflecting continued working capital discipline even as activity levels increased, as well as the benefit of deleveraging debt and pensions. Total voluntary pension contributions of €0.8 billion since Q4 2019 generate an improvement of more than €100 million per annum.
- Progress on **portfolio simplification**, with the closure of 5 business line divestments in the first quarter and the last one occurring in Q2 2021.
- Reinvesting in **Solvay One Planet**, including a decision to invest further in energy transition at our Rheinberg Soda Ash plant with a complete phase out of coal. This action not only enables the site to be the lowest soda ash CO₂ emitter globally (irrespective of production process being natural or synthetic), but also creates significant economic value.

Underlying, (in € million)	Q1 2021	Q1 2020	% уоу	% organic
Net sales	2,373	2,474	-4.1%	+1.9%
EBITDA	583	569	+2.5%	+10.3%
EBITDA margin	24.6%	23.0%	+1.6pp	-
FCF to shareholders from continuing operations	282	202	+39.8%	-
FCF conversion ratio (LTM)	54.8%	40.4%	+14.4pp	-

CEO Quote

"First quarter results reflect the continued economic recovery visible across many of our markets. I am pleased to see that our disciplined structural actions taken last year to lower the company's cost base have enabled strong quality of earnings. We have also maintained our sharp focus on cash management, delivering eight consecutive quarters of positive free cash flow generation. Looking ahead, we are investing in our growth platforms, our front line, and in innovation that will support sustainable top line growth across the mid-term."

2021¹ Outlook

Full year underlying EBITDA is estimated between €2.0 and €2.2 billion, and Free Cash Flow is estimated around €650 million, up from the prior estimate between €600 and €650 million.

 $^{^{1}\,}$ Barring additional deterioration related to a third wave of Covid-19 in the second half.

Key figures


Underlying key figures

(in € million)	Q1 2021	Q1 2020	% уоу
Net sales	2,373	2,474	-4.1%
EBITDA	583	569	+2.5%
EBITDA margin	24.6%	23.0%	+1.6pp
EBIT	382	371	+2.9%
Net financial charges	-63	-68	+8.4%
Income tax expenses	-70	-76	+7.7%
Tax rate	24%	26%	-2.7pp
Profit from discontinued operations	1	21	n.m.
(Profit) / loss attributable to non-controlling interests	-9	-11	-14.8%
Profit / (loss) attributable to Solvay shareholders	240	236	+1.8%
Basic earnings per share (in €)	2.33	2.28	+1.9%
of which from continuing operations	2.31	2.08	+11.2%
Capex in continuing operations	100	163	-38.6%
FCF to Solvay shareholders from continuing operations	282	202	+39.8%
FCF to Solvay shareholders	282	197	+43.0%
FCF conversion ratio (LTM)	54.8%	40.4%	+14.4pp
Net financial debt	4,157		
Underlying leverage ratio	2.1		

Group performance

Net sales


Net sales of $\in 2,373$ million in Q1 2021 were down 4.1% due mainly to the 5.9% negative impact from currency and scope, but up 1.9% organically. First quarter sales (+7% sequentially), marks the third consecutive sequential increase, reflecting improving market conditions across most businesses, especially in automotive, electronics, mining and construction industries. Volume growth in each of these markets combined with a supportive pricing environment drove the organic



sales increase, which was partially offset by lower volumes in civil aerospace. Geographically, all regions progressed sequentially, with sales in China up by 30% versus the first quarter 2020.


Underlying EBITDA

Underlying EBITDA of $\notin 583$ million was up 2.5% (+10.3% organically) in Q1 2021 as a result of higher sales and $\notin 80$ million of additional structural cost savings. As a result, the EBITDA margin reached a record 24.6% in the quarter.




Free cash flow

Free cash flow to shareholders from continuing operations reached €282 million, a 40% increase versus Q1 2020, reflecting continued discipline in working capital management, with working capital to sales ratio reaching 12% in Q1 2021. FCF was further supported by lower cash costs related to improvements in pension management.



Underlying net debt


Underlying net financial debt was roughly stable at ≤ 4.2 billion compared to December 2020, with strong free cash flow generation, the proceeds from divestments, the ≤ 52 million purchase of the EBRD shares in the Solvay holding of the Rusvinyl Joint Venture, and the ≤ 102 million additional voluntary pension contributions made in Belgium in January 2021. Credit ratings



remain strong at BBB (S&P) and Baa2 (Moody's), and the outlook is now stable for both agencies following a recent improvement in outlook by Moody's.

Provisions

Provisions are down by €208 million to €2.9 billion compared to December 2020, primarily related to €102 million voluntary pension contributions in Belgium and the impact of higher discount rates, and despite a €174 million non-cash restructuring provision related to the cost savings plan in Solvay announced February. continues to make progress on its pension fundina roadmap, with cumulative funding of €768 million since



Q4 2019, which has significantly reduced annual pension cash costs by more than €100 million.

Performance by segments

Net sales bridges

Net sales Q1	Underlying					
(in € million)	Q1 2020	Scope	Forex conversion	Volume & mix	Price	Q1 2021
Solvay	2,474	-16	-130	40	4	2,373
Materials	789	-8	-36	-51	-5	689
Chemicals	800	-3	-52	29	16	791
Solutions	883	-4	-42	62	-8	891
CBS	1	-	-	1	-	3

Materials

Sales in Q1 2021 were down 12.7% (7.5% organically) as headwinds in civil aero continue to weigh on the segment; a significant part of the decline was supported by continued recovery in specialty polymers.

Sales in Specialty Polymers increased by +6.3% (+10% organically) compared to the first quarter of 2020, and by +12% sequentially versus the fourth quarter 2020. This was driven by the continued strong demand in the automotive industry, partly related to the restocking effect. Automotive sales were up +19% versus Q1 2020, led by 80% growth in batteries for hybrid and electric vehicles. Other markets, including electronics and building were also solid, while healthcare was a bit softer than last year. Strong volume growth in Specialty Polymers was able to offset part of the headwinds related to civil aerospace.

Composite Materials sales were down 42.3% (36.6% organically) year on year, but improved by +8.6% sequentially versus the fourth quarter 2020. As expected, civil aerospace remains challenged yet improved sequentially compared to Q4 2020, while the defense and space sectors remain resilient.

Segment EBITDA decreased by 9.7% (4.7% organically) year on year, but was up +35% sequentially versus Q4, demonstrating the cost savings initiatives implemented in 2020, mainly attributed to the Composite Materials business following two plant closures. Pricing was sustained despite the various headwinds (raw material, supply chain and logistics issues). These initiatives supported a strong EBITDA margin of 29.9%.

Chemicals

First quarter 2021 sales in the segment were down 1.2% including forex and scope, but up +6.1% organically.

Soda Ash sales continued to improve sequentially, though were still 5.9% lower (-3.0% organically) than Q1 2020. The continuing recovery in building sustained good demand in flat glass, while demand for container glass used in the HORECA (hospitality, restaurant and catering) industry remained weak.

Peroxide sales were down by 11.1% (-4.7% organically), compared to Q1 2020, due to lower volumes in the pulp and paper markets in North America and Europe.

Silica sales were again strong +2.6% yoy (+7.9% organically), thanks to rising demand in the automotive segment, market share gain, and interest in our recently launched innovations.

Coatis had exceptional sales in this quarter, up +23.5% (+55% organically) with higher volumes and higher prices as a result of favorable market conditions.

Segment EBITDA was up +0.6% compared to Q1 2020 (+8.7% organically), and increased sequentially by 14.6% versus the fourth quarter 2020, as a result of favorable market conditions in Coatis combined with lower fixed costs in the business, as well as significant contributions from Rusvinyl, driven by strong PVC demand and higher prices. This resulted in a record underlying EBITDA margin of 30.4% in Q1 2021.

Solutions

Sales in the first quarter of 2021 were up +0.9% (+6.4% organically) due mainly to higher volumes across most major markets.

First quarter sales in Novecare increased organically by 4.9% year on year, and increased organically by 13% excluding oil & gas; growth was driven by higher volumes in coatings, home & personal care, and agro markets. Oil & gas improved sequentially by +11% versus Q4, yet declined 31% year on year.

Special Chem sales increased +2.7% (organically by +8.6%) year on year thanks to the continued recovery in the automotive industry and sustained strong demand in the electronics market.

Technology Solutions sales increased by +9.4% (+14.5% organically) compared to Q1 2020 thanks to Copper mine site re-openings driving higher production levels and greater demand for our extractant solutions. Sequential sales versus Q4 improved by a similar magnitude.

Aroma Performance sales increased sequentially by +11.6% in Q1 versus Q4, due to strong volumes across product lines, but were down organically by 1.6% compared to a very strong Q1 2020. The business is investing to increase capacity in natural vanilla to capture the opportunity in this fast growing market.

First quarter EBITDA in the segment was up +12.4% (+21.1% organically) year and year, and up 26% sequentially, reflecting the continued recovery across most markets. EBITDA margin in the segment was up +2pp to 19.4% in Q1 2021, further reflecting our cost reduction improvements across all businesses.

Segment review	Underlying			
(in € million)	Q1 2021	Q1 2020	% уоу	% organic
Net sales	2,373	2,474	-4.1%	+1.9%
Materials	689	789	-12.7%	-7.5%
Specialty Polymers	511	481	+6.3%	+10.0%
Composite Materials	178	308	-42.3%	-36.6%
Chemicals	791	800	-1.2%	+6.1%
Soda Ash & Derivatives	367	390	-5.9%	-3.0%
Peroxides	152	172	-11.1%	-4.7%
Coatis	157	127	+23.5%	+55.1%
Silica	114	111	+2.6%	+7.9%
Solutions	891	883	+0.9%	+6.4%
Novecare	416	421	-1.3%	+4.9%
Special Chem	211	206	+2.7%	+8.6%
Technology Solutions	154	140	+9.4%	+14.5%
Aroma Performance	110	116	-5.0%	-1.6%
Corporate & Business Services	3	1	+81.4%	+94.1%
EBITDA	583	569	+2.5%	+10.3%
Materials	206	228	-9.7%	-4.7%
Chemicals	240	239	+0.6%	+8.7%
Solutions	173	154	+12.4%	+21.1%
Corporate & Business Services	-36	-52	+30.3%	-
EBITDA margin	24.6%	23.0%	+1.6pp	-
Materials	29.9%	28.9%	+1.0pp	-
Chemicals	30.4%	29.8%	+0.5pp	-
Solutions	19.4%	17.4%	+2.0pp	-

Key IFRS figures

Q1 key figures		IFRS			Underlying	
(in € million)	Q1 2021	Q1 2020	% уоу	Q1 2021	Q1 2020	% уоу
Net sales	2,373	2,474	-4.1%	2,373	2,474	-4.1%
EBITDA	414	485	-14.7%	583	569	+2.5%
EBITDA margin				24.6%	23.0%	+1.6pp
EBIT	169	233	-27.5%	382	371	+2.9%
Net financial charges	-30	-27	-11.8%	-63	-68	+8.4%
Income tax expenses	-25	-47	+46.2%	-70	-76	+7.7%
Tax rate				24%	26%	-2.7pp
Profit from discontinued operations	-	102	n.m.	1	21	n.m.
(Profit) / loss attributable to non-controlling interests	-9	-11	-16.3%	-9	-11	-14.8%
Profit / (loss) attributable to Solvay shareholders	104	249	-58.3%	240	236	+1.8%
Basic earnings per share (in €)	1.01	2.41	-58.3%	2.33	2.28	+1.9%
of which from continuing operations	1.01	1.43	-29.5%	2.31	2.08	+11.2%
Capex in continuing operations				100	163	-38.6%
FCF to Solvay shareholders from continuing operations				282	202	+39.8%
FCF to Solvay shareholders				282	197	+43.0%
Net financial debt				4,157		
Underlying leverage ratio				2.1		

Supplementary information

Reconciliation of alternative performance metrics

Solvay measures its financial performance using alternative performance metrics, which can be found below. Solvay believes that these measurements are useful for analyzing and explaining changes and trends in its historical results of operations, as they allow performance to be compared on a consistent basis. Definitions of the different metrics presented here are included in the glossary at the end of this financial report.

Tax rate		Under	rlying
(in € million)		Q1 2021	Q1 2020
Profit / (loss) for the period before taxes	а	319	302
Earnings from associates & joint ventures	b	29	21
Interests and realized foreign exchange gains (losses) on the RusVinyl joint venture	С	-7	-8
Income taxes	d	-70	-76
Tax rate	e = -d/(a-b-c)	24%	26%

Free cash flow (FCF)

(in € million)		Q1 2021	Q1 2020
Cash flow from operating activities	а	303	-58
of which voluntary pension contributions	b	-102	-460
Cash flow from investing activities	С	7	1,095
of which capital expenditures required by share sale agreement	d	-	-14
Acquisition (-) of subsidiaries	е	-2	-9
Acquisition (-) of investments - Other	f	-1	-24
Loans to associates and non-consolidated companies	g	7	7
Sale (+) of subsidiaries and investments	h	77	1,292
Increase/decrease of borrowings related to environmental remediation	i	-	5
Payment of lease liabilities	j	-22	-28
FCF	k = a-b+c-d-e-f-g-h+i+j	308	220
FCF from discontinued operations	1	-	-4
FCF from continuing operations	m = k-l	308	225
Net interests paid	n	-7	-8
Coupons paid on perpetual hybrid bonds	0	-19	-13
Dividends paid to non-controlling interests	р	-	-2
FCF to Solvay shareholders	q = k+n+o+p	282	197
FCF to Solvay shareholders from discontinued operations	r	-	-4
FCF to Solvay shareholders from continuing operations	s = q-r	282	202
FCF to Solvay shareholders from continuing operations (LTM)	t	1,043	898
Dividends paid to non-controlling interests from continuing operations (LTM)	u	-31	-39
Underlying EBITDA (LTM)	V	1,959	2,319
FCF conversion ratio (LTM)	w = (t-u)/v	54.8%	40.4%

Net working capital		2021	2020
(in € million)		March 31	December 31
Inventories	а	1,400	1,241
Trade receivables	b	1,513	1,264
Other current receivables	С	701	519
Trade payables	d	-1,426	-1,197
Other current liabilities	e	-907	-720
Net working capital	f = a+b+c+d+e	1,281	1,107
Sales	g	2,604	2,418
Annualized quarterly total sales	h = 4*g	10,416	9,673
Net working capital / sales	i = f / h	12.3%	11.4%

Capital expenditure (capex)

(in € million)		Q1 2021	Q1 2020
Acquisition (-) of tangible assets	а	-64	-146
Acquisition (-) of intangible assets	b	-14	-22
Payment of lease liabilities	C	-22	-28
Сарех	d = a+b+c	-100	-196
Capex in discontinued operations	e	-	-33
Capex in continuing operations	f = d-e	-100	-163
Underlying EBITDA	g	583	569
Cash conversion	h = (f+g)/g	82.8%	71.3%

Net financial debt		2021	2020
(in € million)		March 31	December 31
Non-current financial debt	а	-3,286	-3,233
Current financial debt	b	-491	-287
IFRS gross debt	c = a+b	-3,777	-3,519
Underlying gross debt	d = c+h	-5,577	-5,319
Other financial instruments	e	133	119
Cash & cash equivalents	f	1,287	1,002
Total cash and cash equivalents	g = e+f	1,420	1,121
IFRS net debt	i = c+g	-2,357	-2,398
Perpetual hybrid bonds	h	-1,800	-1,800
Underlying net debt	j = i+h	-4,157	-4,198
Underlying EBITDA (LTM)	k	1,959	1,945
Adjustment for discontinued operations	l	-	-
Adjusted underlying EBITDA for leverage calculation	m = k+l	1,959	1,945
Underlying leverage ratio		2.1	2.2

Reconciliation of underlying income statement indicators

Besides IFRS accounts, Solvay also presents underlying Income Statement performance indicators to provide a more consistent and comparable indication of Solvay's economic performance. These figures adjust IFRS figures for the non-cash Purchase Price Allocation (PPA) accounting impacts related to acquisitions, for the coupons of perpetual hybrid bonds classified as equity under IFRS but treated as debt in the underlying statements, and for other elements to generate a measure that avoids distortion and facilitates the appreciation of performance and comparability of results over time.

Q1 consolidated income statement		Q1 2021			Q1 2020	
		Adjust-	Under-		Adjust-	Under-
(in € million)	IFRS	ments	lying	IFRS	ments	lying
Sales	2,604	-	2,604	2,687	-	2,687
of which revenues from non-core activities	231	-	231	213	-	213
of which net sales	2,373	-	2,373	2,474	-	2,474
Cost of goods sold	-1,869	-	-1,869	-1,944	-	-1,943
Gross margin	735	-	735	743	-	744
Commercial costs	-71	-	-71	-87	-	-87
Administrative costs	-220	-	-220	-244	6	-238
Research & development costs	-94	1	-93	-78	1	-78
Other operating gains & losses	-36	38	2	-36	44	8
Earnings from associates & joint ventures	29	-1	29	4	17	21
Result from portfolio management & major restructuring	-161	161	-	-58	58	-
Result from legacy remediation & major litigations	-14	14	-	-12	12	-
EBITDA	414	169	583	485	83	569
Depreciation, amortization & impairments	-245	43	-201	-252	54	-198
EBIT	169	213	382	233	138	371
Net cost of borrowings	-26	-	-26	-26	-	-26
Coupons on perpetual hybrid bonds	-	-20	-20	-	-24	-24
Interests and realized foreign exchange gains (losses) on the RusVinyl joint venture	-	-7	-7	-	-8	-8
Cost of discounting provisions	-4	-5	-9	-1	-10	-11
Profit / (loss) for the period before taxes	139	180	319	206	96	302
Income taxes	-25	-45	-70	-47	-29	-76
Profit / (loss) for the period from continuing operations	113	135	248	159	67	226
Profit / (loss) for the period from discontinued operations	-	1	1	102	-81	21
Profit / (loss) for the period	113	136	250	261	-13	247
attributable to Solvay shareholders	104	136	240	249	-13	236
attributable to non-controlling interests	9	-	9	11	-	11
Basic earnings per share (in €)	1.01	1.32	2.33	2.41	-0.13	2.28
of which from continuing operations	1.01	1.31	2.31	1.43	0.65	2.08
Diluted earnings per share (in €)	1.01	1.32	2.32	2.41	-0.13	2.28
of which from continuing operations	1.00	1.31	2.31	1.43	0.65	2.08

EBITDA on an IFRS basis totaled €414 million, versus €583 million on an underlying basis. The difference of €169 million is explained by the following adjustments to IFRS results, which are done to improve the comparability of underlying results:

- €-1 million in "*Earnings from associates & joint ventures*" for Solvay's share in the financial charges of the Rusvinyl joint venture and the foreign exchange losses on the €-denominated debt of the joint venture, the Russian ruble being stable vs EUR over the period. These elements are reclassified in "*Net financial charges*".
- €156 million to adjust for the "*Result from portfolio management and major restructuring*", excluding depreciation, amortization and impairment elements, mainly related to the new restructuring plan launched in Q1 2021 (€150 million).
- €14 million to adjust for the "*Result from legacy remediation and major litigations"*, primarily indemnities for environmental remediation.

EBIT on an IFRS basis totaled €169 million, versus €382 million on an underlying basis. The difference of €213 million is explained by the above-mentioned €169 million adjustments at the EBITDA level and €43 million of "Depreciation, amortization & impairments". The latter consist of:
€38 million to adjust for the non-cash impact of purchase price allocation (PPA), consisting of amortization

- €38 million to adjust for the non-cash impact of purchase price allocation (PPA), consisting of amortization charges on intangible assets, which are adjusted in "*Research & development costs*" for €1 million, and in "*Other operating gains & losses*" for €38 million.
- €5 million to adjust for the impact of impairments reported in "*Result from portfolio management and major restructuring*" resulting primarily from the impairment of non performing assets

Net financial charges on an IFRS basis were €-30 million versus €-62 million on an underlying basis. The €-32 million adjustment made to IFRS net financial charges consists of:

- €-20 million reclassification of coupons on perpetual hybrid bonds, which are treated as dividends under IFRS, and as financial charges in underlying results.
- €-7 million reclassification of financial charges and realized foreign exchange result on the €-denominated debt of RusVinyl as net financial charges.
- €-5 million for the net impact of decreasing discount rates on the valuation of environmental liabilities in the period.

Income taxes on an IFRS basis were €-25 million, versus €-70 million on an underlying basis. The €-45 million adjustment mainly relates to the adjustments of the earnings before taxes described above.

Profit / (loss) attributable to Solvay shareholders was \in 104 million on an IFRS basis and \in 240 million on an underlying basis. The delta of \in 136 million reflects the above-mentioned adjustments to EBIT, net financial charges, income taxes and minor adjustments for discontinued operations. There was no impact from non-controlling interests.

Condensed consolidated financial statements^[1]

Consolidated income statement		IFRS		
(in € million)	Q1 2021	Q1 2020		
Sales	2,604	2,687		
of which revenues from non-core activities	231	213		
of which net sales	2,373	2,474		
Cost of goods sold	-1,869	-1,944		
Gross margin	735	743		
Commercial costs	-71	-87		
Administrative costs	-220	-244		
Research & development costs	-94	-78		
Other operating gains & losses	-36	-36		
Earnings from associates & joint ventures	29	4		
Result from portfolio management & major restructuring [2]	-161	-58		
Result from legacy remediation & major litigations	-14	-12		
EBIT	169	233		
Cost of borrowings	-28	-29		
Interest on loans & short term deposits	2	3		
Cost of discounting provisions	-4	-1		
Profit / (loss) for the period before taxes	139	206		
Income taxes	-25	-47		
Profit / (loss) for the period from continuing operations	113	159		
attributable to Solvay shareholders	104	148		
attributable to non-controlling interests	9	11		
Profit / (loss) for the period from discontinued operations	-	102		
Profit / (loss) for the period	113	261		
attributable to Solvay shareholders	104	249		
attributable to non-controlling interests	9	11		
Weighted average of number of outstanding shares, basic	103,276,287	103,313,847		
Weighted average of number of outstanding shares, diluted	103,454,065	103,418,888		
Basic earnings per share (in €)		2.41		
of which from continuing operations	1.01	1.43		
Diluted earnings per share (in €)		2.41		
of which from continuing operations	1.00	1.43		

Consolidated statement of comprehensive income

Consolidated statement of comprehensive income		IFRS		
(in € million)	Q1 2021	Q1 2020		
Profit / (loss) for the period	113	261		
Gains and losses on hedging instruments in a cash flow hedge	-11	-48		
Currency translation differences from subsidiaries & joint operations	244	-2		
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss	11	-72		
Recyclable components	244	-122		
Gains and losses on equity instruments measured at fair value through other comprehensive income	3	1		
Remeasurement of the net defined benefit liability [3]	273	35		
Share of other comprehensive income of associates and joint ventures accounted for using equity method that will not be reclassified to profit or loss	-	1		
Non-recyclable components	276	37		
Income tax relating to components of other comprehensive income	-46	-6		
Other comprehensive income, net of related tax effects	474	-90		
Total comprehensive income		170		
attributed to Solvay share	574	157		
attributed to non-controlling interests	13	13		

[1] Unaudited.

[2] Q1 2021 Result from portfolio management & major restructuring mainly relates to the \in 150 million provision in relation with the new strategic transformation announced in February, resulting in a net reduction of approximately 500 roles. [3] The remeasurement of the net defined benefit liability of \in 273 million in Q1 2021 was mainly due to increase of discount rates applicable to post-employment provisions in the Euro-zone, the UK and US, partly offset by the return of plan assets.

Consolidated statement of cash flows		IFRS		
(in € million)	Q1 2021	Q1 2020		
Profit / (loss) for the period	113	26		
Adjustments to profit / (loss) for the period	444	324		
Depreciation, amortization & impairments (-)	245	252		
Earnings from associates & joint ventures (-)	-29	-4		
Additions & reversals on provisions (-)	185	114		
Other non-operating and non-cash items [1]	-11	-312		
Net financial charges (-)	29	27		
Income tax expenses (-)	25	246		
Changes in working capital	-67	-137		
Uses of provisions	-63	-75		
Voluntary pension contributions	-102	-460		
Dividends received from associates & joint ventures	18			
Income taxes paid (excluding income taxes paid on sale of investments)	-40	26		
Cash flow from operating activities	303	-58		
Acquisition (-) of subsidiaries	-2	-6		
Acquisition (-) of investments - Other	-1	-24		
Loans to associates and non-consolidated companies	7	-		
Sale (+) of subsidiaries and investments	77	1,292		
Acquisition (-) of tangible and intangible assets (capex)	-78	-168		
of which tangible assets	-64	-146		
of which capital expenditures required by share sale agreement	-	-14		
of which intangible assets	-14	-22		
Sale (+) of tangible & intangible assets	10	Ę		
Changes in non-current financial assets	-7	-6		
Cash flow from investing activities	7	1,09		
Sale (acquisition) of treasury shares	37	-26		
Increase in borrowings	161	249		
Repayment of borrowings [2]	-3	-84		
Changes in other current financial assets	-10	-22		
Payment of lease liabilities	-22	-28		
Net interests paid	-7	-6		
Coupons paid on perpetual hybrid bonds	-19	-1:		
Dividends paid	-155	-15		
of which to Solvay shareholders	-155	-15		
of which to non-controlling interests	-	-:		
Other [3]	-11	-62		
Cash flow from financing activities	-30	-91		
of which increase/decrease of borrowings related to environmental remediation	-			
Net change in cash and cash equivalents	280	124		
Currency translation differences	-2	-44		
Opening cash balance [4]	1,009	809		
Closing cash balance	1,287	889		

[1] Other non-operating and non-cash items of €-312 million in Q1 2020 mainly relates to Polyamide capital gain before taxes and provisions
[2] Repayment of borrowings of €-845 million in Q1 2020 mainly relates to the reimbursement of commercial paper after the cash proceeds on Polyamide disposal.
[3] Other cash flow from financing activities of €-11 million mainly includes the payment for the purchase of the EBRD shares in the Solvay holding of the Rusvinyl Joint Venture, following the exercise of the Solvay call option (€-52m) and cash inflows related to margin calls (€+36m).
[4] of which €7 million cash in assets held for sale at the end of 2020.

Statement of cash flow from discontinued operations		IFRS		
(in € million)		Q1 2020		
Cash flow from operating activities		15		
Cash flow from investing activities		-33		
Cash flow from financing activities	-	5		
Net change in cash and cash equivalents		-13		

The cash flow from investing activities of discontinued operations excludes the proceeds received on the divestment of Polyamide. The sale of Polyamide was completed on January 31, 2020.

Consolidated statement of financial position	2021	2020
(in € million)	March 31	December 31
Intangible assets	2,154	2,141
Goodwill	3,328	3,265
Tangible assets	4,752	4,717
Right-of-use assets	408	405
	70	66
Equity instruments measured at fair value through other comprehensive income		
Investments in associates & joint ventures	520	495
Other investments	42	42
Deferred tax assets	735	788
Loans & other assets	402	390
Non-current assets	12,411	12,308
Inventories Trade receivables	1,400	1,241 1,264
Income tax receivables	1,513	1,204
Dividends receivable	3	109
Other financial instruments	133	- 119
Other infancial instruments	701	519
	1,287	1,002
Cash & cash equivalents Assets held for sale	67	229
Current assets	5,212	4,484
Total assets	17,624	16,792
Share capital	1,588	1,588 1,170
Issue premiums Other reserves	1,170 5,033	4,439
Non-controlling interests	118	4,439
	7,909	7,304
Total equity Provisions for employee benefits	1,854	2,209
Other provisions	700	2,209
Deferred tax liabilities	493	487
Financial debt	3,286	3,233
Other liabilities	100	<u> </u>
Non-current liabilities	6,433	6,713
Other provisions	324	190
Financial debt [1]	491	287
Trade payables	1,426	1,197
Income tax payables	110	113
Dividends payable	5	159
Other liabilities	907	720
Liabilities associated with assets held for sale	17	110
	17 3,281	110 2,775

The current financial debt (€491 million at the end of March 2021) is composed of short term financing (which include €96 million of short term portion of leases).

Consolidated statement of change	es in equity						Revaluation r (fair valu					
(in € million)	Share capital	Share premiums	Treasury shares	Perpetual hybrid bonds	Retained earnings	Currency translation differences	Equity instruments measured at fair value through other comprehensive income	Cash flow hedges	Defined benefit pension plans	Total other reserves	Non- controlling interests	Total equity
Balance on December 31, 2019	1,588	1,170	-274	1,789	6,462	-454	10	-20	-756	6,757	110	9,625
Profit / (loss) for the period	-	-	-	-	249	-	-	-	-	249	11	261
Items of other comprehensive income	-	-	-	-	-	-76	1	-33	15	-93	2	-90
Comprehensive income	-	-	-	-	249	-76	1	-33	15	157	13	170
Cost of stock options	-	-	-	-	1	-	-	-	-	1	-	1
Dividends	-	-	-	-	-	-	-	-	-	-	-2	-2
Coupons of perpetual hybrid bonds	-	-	-	-	-13	-	-	-	-	-13	-	-13
Sale (acquisition) of treasury shares	-	-	-26	-	-	-	-	-	-	-26	-	-26
Other	-	-	-	-	-6	-	-	-	5	-1	-	-1
Balance on March 31, 2020	1,588	1,170	-300	1,789	6,694	-530	11	-53	-736	6,875	122	9,754
Balance on December 31, 2020	1,588	1,170	-286	1,786	4,985	-1,153	12	14	-919	4,439	106	7,304
Profit / (loss) for the period	-	-	-	-	104	-	-	-	-	104	9	113
Items of other comprehensive income	-	-	-	-	-	251	2	-9	226	470	4	474
Comprehensive income	-	-	-	-	104	251	2	-9	226	574	13	588
Cost of stock options	-	-	-	-	2	-	-	-	-	2	-	2
Dividends	-	-	-	-	-	-	-	-	-	-	-1	-2
Coupons of perpetual hybrid bonds	-	-	-	-	-19	-	-	-	-	-19	-	-19
Sale (acquisition) of treasury shares	-	-	37	-	-	-	-	-	-	37	-	37
Other	-	-	-	-	-10	-	-	-	10	-	-	-
Balance on March 31, 2021	1,588	1,170	-249	1,786	5,062	-902	14	5	-683	5,033	118	7,909

Q1 2021 Equity increased by € 251 million after currency translation differences mainly due to the USD revaluation against EUR in the quarter.

Notes to the condensed consolidated financial statements

1. General information and significant events

Solvay is a public limited liability company governed by Belgian law and quoted on Euronext Brussels and Euronext Paris. These condensed consolidated financial statements were authorized for issue by the Board of Directors on May 4, 2021.

On January 18, 2021 Solvay sent a Call option Notice to the European Bank for Reconstruction and Development (EBRD) to purchase the EBRD shares in the Solvay holding of the Rusvinyl Joint Venture. The option price of \in 52 million was booked as an Other current liability at the end of 2020 and has been paid in Q1 2021.

An additional voluntary contribution of €102 million was made in January 2021 to the Belgian pension plans.

In January, Solvay launched a new chapter of its strategic transformation aimed to further align its structure to its G.R.O.W. strategy. This builds on previous plans announced in 2020, and represents a profound simplification of all support functions to serve the business more effectively. The plan will lead to an additional net reduction of approximately 500 roles by the end of 2022 and incremental cost savings of ϵ 75 million. As a consequence of the new restructuring plan, a non-cash restructuring provision of around ϵ 150 million was recognized in Q1 2021.

In February, Solvay reached an agreement to purchase a seed coating technology to bolt-on to its existing agro products within the Novecare business. This is a natural extension to Solvay's own AgRHO® family of sustainable seed boosting solutions and supports the drive toward more bio-based, sustainable technologies. The transaction is expected to close in Q2 2021.

Assets held for sale

During Q1, 2021, the assets and liabilities related to the following businesses previously classified as "held for sale" were divested:

- the Peroxides sodium chlorate business line and related assets in Povoa (Portugal),
- the various fluorine chemicals assets in Onsan, South Korea, part of Special Chem,
- the Peroxides sodium percarbonate business line and related assets in Bad Hönningen (Germany),
- the Barium Strontium business and the joint venture with Chemical Products Corporation (CPC) and
- the Process Materials business (part of Composites)

At the end of March 2021, the commodity amphoterics surfactants activities in Novecare, are the only business still classified as held for sale.

COVID-19 impact

The total net impact of COVID-19 on Q1 2021 EBITDA was not considered to be material to the Group as the short-term mitigation actions related to labor costs (including furloughs) and indirect spend were substantially completed at December 31, 2020. The Group will continue to monitor any future evolution of the sanitary crisis.

2. Accounting policies

Solvay prepares its condensed consolidated interim financial statements on a quarterly basis, in accordance with IAS 34 "*Interim Financial Reporting*" using the same accounting policies as those adopted for the preparation of the consolidated financial statements for the year ended December 31, 2020. They do not include all the information required for the preparation of the annual consolidated financial statements and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2020. The consolidated financial statements for the year ended December 31, 2020. The consolidated financial statements for the year ended December 31, 2020. The consolidated financial statements for 2020 were published in April 2021. The critical accounting judgments and key sources of estimation uncertainty included in the 2020 annual report remain applicable. Relevant updates on specific topics are included in these notes and should be read together with the 2020 annual report.

During Q1, 2021, IBOR Reform Phase 2 became effective for the Group and its adoption did not have an impact on the consolidated financial statements during the period. Going forward the Group's management will continue to monitor the market evolution resulting from the decisions taken by each of the relevant authorities of such benchmarks, however, based on the current understanding IBOR Reform Phase 2 is not expected to have more than an insignificant impact on the Group's consolidated financial statements.

3. Segment information

Solvay is organized in the following operating segments:

- <u>Materials</u> offer a unique portfolio of high-performance polymers and composite technologies used primarily in sustainable mobility applications. Its solutions enable weight reduction and enhance performance while improving CO₂ and energy efficiency. Major markets served include next-generation mobility in automotive and aerospace, healthcare and electronics.
- <u>Chemicals</u> host chemical intermediate businesses focused on mature and resilient markets. Solvay is a world leader in soda ash and peroxides and major markets served include building and construction, consumer goods and food. Its Silica, Coatis and RusVinyl businesses are also high quality assets with strong positions in their markets. This segment provides resilient cash flows and the company selectively invests in these businesses to become the #1 cash conversion chemical player.
- <u>Solutions</u> offer a unique formulation & application expertise through customized specialty formulations for surface chemistry & liquid behavior, maximizing yield and efficiency of the processes they are used in while minimizing the eco-impact. Novecare, Technology Solutions, Aroma and Special Chem focus on specific areas such as resources (improving the extraction yield of metals, minerals and oil), industrial applications (such as coatings) or consumer goods and healthcare (including vanillin and guar for home and personal care).
- <u>Corporate & Business Services</u> includes corporate and other business services, such as Group research & innovation or energy services, whose mission is to optimize energy consumption and reduce CO₂ emissions.

(in € million)	Q1 2021	Q1 2020
Net sales	2,373	2,474
Materials	689	789
Chemicals	791	800
Solutions	891	883
Corporate & Business Services	3	1
Underlying EBITDA	583	569
Materials	206	228
Chemicals	240	239
Solutions	173	154
Corporate & Business Services	-36	-52
Underlying depreciation, amortization & impairments	-201	-198
Underlying EBIT	382	371
Non-cash accounting impact from amortization & depreciation of purchase price allocation (PPA) from acquisitions	-38	-51
Net financial charges and remeasurements of equity book value of the RusVinyl joint venture	1	-17
Result from portfolio management & major restructuring	-161	-58
Result from legacy remediation & major litigations	-14	-12
EBIT	169	233
Net financial charges	-30	-27
Profit / (loss) for the period before taxes	139	206
Income taxes	-25	-47
Profit / (loss) for the period from continuing operations	113	159
Profit / (loss) for the period from discontinued operations	-	102
Profit / (loss) for the period	113	261
attributable to non-controlling interests	9	11
attributable to Solvay shareholders	104	249

Reconciliation of segment, underlying and IFRS data

The non-cash PPA impacts can be found in the reconciliation table on page 11.

4. Financial Instruments

Valuation techniques

Compared to December 31, 2020, there are no changes in valuation techniques.

Fair value of financial instruments measured at amortized cost

For all financial instruments not measured at fair value in Solvay's consolidated statement of financial position, the fair value of those financial instruments as of March 31, 2021, is not significantly different from the ones published in Note F35 of the consolidated financial statements for the year ended December 31, 2020.

Financial instruments measured at fair value

For financial instruments measured at fair value in Solvay's consolidated statement of financial position, the fair value of those instruments as of March 31, 2021, is not significantly different from the ones as published in the Note F35 of the consolidated financial statements for the year ended December 31, 2020.

5. Events after the reporting period

There were no material events after the reporting period.

6. Declaration by responsible persons

Ilham Kadri, Chief Executive Officer, and Karim Hajjar, Chief Financial Officer, of the Solvay Group, declare that to the best of their knowledge:

- The condensed consolidated financial information, prepared in accordance with IAS 34 "*Interim Financial Reporting*" as adopted by the European Union, reflects a faithful image of the assets and liabilities, financial situation and results of the Solvay Group;
- The management report contains a faithful presentation of significant events occurring during the first three months of 2021, and their impact on the condensed consolidated financial information;
- The main risks and uncertainties are in accordance with the assessment disclosed in the Risk Management section of the Solvay 2020 Annual Integrated Report, taking into account the current economic and financial environment.

Glossary

Adjustments: Each of these adjustments made to the IFRS results is considered to be significant in nature and/or value. Excluding these items from the profit metrics provides readers with relevant additional information on the Group's underlying performance over time because it is consistent with how the business' performance is reported to the Board of Directors and the Executive Committee. These adjustments consist of:

- Results from portfolio management and major restructurings,
- Results from legacy remediation and major litigations,
- Amortization of intangible assets resulting from Purchase Price Allocation (PPA) and inventory step-up in gross margin,
- Net financial results related to changes in discount rates, coupons of hybrid bonds deducted from equity under IFRS and debt management impacts (mainly including gains/(losses) related to the early repayment of debt,
- Adjustments of equity earnings for impairment gains or losses and unrealized foreign exchange gains or losses on debt,
- Results from equity instruments measured at fair value through other comprehensive income,
- Tax effects related to the items listed above and tax expense or income of prior years
- All adjustments listed above apply to both continuing and discontinuing operations, and include the impacts on non-controlling interests

Basic earnings per share: Net income (Solvay's share) divided by the weighted average number of shares, after deducting own shares purchased to cover stock option programs.

Capital expenditure (capex): Cash paid for the acquisition of tangible and intangible assets presented in cash flows from investing activities, and cash paid on the lease liabilities (excluding interests paid), presented in cash flows from financing activities. This indicator is used to manage capital employed in the Group.

Cash conversion: Is a ratio used to measure the conversion of EBITDA into cash. It is defined as (Underlying EBITDA + Capex from continuing operations) / Underlying EBITDA.

CFROI: Cash Flow Return On Investment measures the cash returns of Solvay's business activities. Movements in CFROI levels are relevant indicators for showing whether economic value is being added, though it is accepted that this measure cannot be benchmarked or compared with industry peers. The definition uses a reasonable estimate (management estimate) of the replacement cost of assets and avoids accounting distortions, e.g. for impairments. It is calculated as the ratio between recurring cash flow and invested capital, where:

- Recurring cash flow = Underlying EBITDA + (Dividends from associates and joint ventures Underlying Earnings from associates and joint ventures) + Recurring capex + Recurring income taxes;
- Invested capital = Replacement value of goodwill & fixed assets + Net working capital + Carrying amount of associates and joint ventures;
- Recurring capex is normalized at 2,3% of the Replacement value of fixed assets net of Goodwill;
- Recurring income taxes are normalized at 28% of (Underlying EBIT Underlying Earnings from associates and joint ventures);

CTA: Currency Translation Adjustment

Diluted earnings per share: Net income (Solvay's share) divided by the weighted average number of shares adjusted for the effects of dilution.

Discontinued operations: Component of the Group which the Group has disposed of or which is classified as held for sale, and:

- Represents a separate major line of business or geographical area of operations;
- Is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or
- Is a subsidiary acquired exclusively with a view to resale

EBIT: Earnings before interest and taxes. Performance indicator that is a measure of the Group's operating profitability irrespective of the funding's structure.

EBITDA: Earnings before interest and taxes, depreciation and amortization. The Group has included EBITDA as an alternative performance indicator because management believes that the measure provides useful information to assess the Group's operating profitability as well as the Group's ability to generate operating cash flows.

Extra-financial indicators: Indicators used that measure the sustainability performance of the company in complement to financial indicators. Solvay has selected 10 indicators that are included in the ONE Planet initiative. For more information, we refer to the last available annual report available on <u>www.solvay.com</u>

Free cash flow: Cash flows from operating activities (excluding cash flows linked to acquisitions or disposals of subsidiaries and cash outflows of Voluntary Pension Contributions, as they are deleveraging in nature as a reimbursement of debt), cash flows from investing activities (excluding cash flows from or related to acquisitions and disposals of subsidiaries, cash flows related to internal management of portfolio (one-off external costs of internal carve-out, related taxes...) and other investments, and excluding loans to associates and non-consolidated investments, and recognition of factored receivables), payment of lease liabilities, and increase/decrease of borrowings related to environmental remediation. Prior to the adoption of IFRS 16, operating lease payments were included within free cash flow. Following the application of IFRS 16, because leases are generally considered to be operating in nature, free cash flow incorporates the payment of the lease liability (excluding the interest expense). Excluding this item in the free cash flow would result in a significant improvement of free cash flow compared to prior periods, whereas the operations themselves have not been affected by the implementation of IFRS 16. It is a measure of cash generation, working capital efficiency and capital discipline of the Group.

Free cash flow to Solvay shareholders: Free cash flow after payment of net interests, coupons of perpetual hybrid bonds and dividends to non-controlling interests. This represents the cash flow available to Solvay shareholders, to pay their dividend and/or to reduce the net financial debt.

Free cash flow conversion: Calculated as the ratio between the free cash flow to Solvay shareholders of the last rolling 12 months (before netting of dividends paid to non-controlling interest) and underlying EBITDA of the last rolling 12 months.

GBU: Global business unit.

HPPO: Hydrogen peroxide propylene oxide, new technology to produce propylene oxide using hydrogen peroxide.

IFRS: International Financial Reporting Standards.

LTM: Last twelve months

Leverage ratio: Net debt / underlying EBITDA of last 12 months. Underlying leverage ratio = underlying net debt / underlying EBITDA of last 12 months.

Mandatory contributions to employee benefits plans: For funded plans, contributions to plan assets corresponding to amounts required to be paid during the respective period, in accordance with agreements with trustees or regulation, as well as, for unfunded plans, benefits paid to beneficiaries.

Net cost of borrowings: cost of borrowings netted with interest on loans and short-term deposits, as well as other gains (losses) on net indebtedness.

Net financial debt: Non-current financial debt + current financial debt – cash & cash equivalents – other financial instruments. Underlying net debt reclassifies as debt 100% of the hybrid perpetual bonds, considered as equity under IFRS. It is a key measure of the strength of the Group's financial position and is widely used by credit rating agencies.

Net financial charges: Net cost of borrowings, and costs of discounting provisions (namely, related to postemployment benefits and Health Safety and Environmental liabilities).

Net pricing: The difference between the change in sales prices versus the change in variable costs.

Net sales: Sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude Revenue from non-core activities.

Net working capital: Includes inventories, trade receivables and other current receivables, netted with trade payables and other current liabilities.

OCI: Other Comprehensive Income.

Operational deleveraging: Reduction of liabilities (net debt or provisions) through operational performance only, i.e. excluding impacts from acquisitions and divestitures, as well as remeasurement impacts (changes of foreign exchange, inflation, mortality and discount rates).

Organic growth: Growth of Net sales or underlying EBITDA excluding scope changes and forex conversion effects. The calculation is made by rebasing the prior period at the business scope and forex conversion rate of the current period.

PA: Polyamide, polymer type.

pp: Unit of percentage points, used to express the evolution of ratios.

PPA: Purchase Price Allocation (PPA) accounting impacts related to acquisitions, primarily for Rhodia and Cytec.

Pricing power: The ability to create positive net pricing.

PSU: Performance Share Unit.

PVC: Polyvinyl chloride, polymer type.

Research & innovation: Research & development costs recognized in the income statement and as capital expenditure before deduction of related subsidies, royalties and depreciation and amortization expense. It measures the total cash effort in research & innovation, regardless of whether the costs were expensed or capitalized.

Research & innovation intensity: Ratio of Research & innovation / net sales

Result from legacy remediation and major litigations: It includes:

- The remediation costs not generated by on-going production facilities (shut-down of sites, discontinued productions, previous years' pollution), and
- The impact of significant litigations

Results from portfolio management and major restructuring: It includes:

- Gains and losses on the sale of subsidiaries, joint operations, joint ventures, and associates that do not qualify as discontinued operations;
- Acquisition costs of new businesses;
- One-off operating external costs related to internal management of portfolio (carve-out of major lines of businesses);
- Gains and losses on the sale of real estate not directly linked to an operating activity;
- Restructuring charges driven by portfolio management and by major reorganization of business activities, including impairment losses resulting from the shutdown of an activity or a plant;
- Impairment losses resulting from testing of Cash Generating Units (CGUs);
- It excludes non-cash accounting impact from amortization and depreciation resulting from the purchase price allocation (PPA) from acquisitions

Revenue from non-core activities: Revenues primarily comprising commodity and utility trading transactions and other revenue, considered to not correspond to Solvay's know-how and core business.

ROCE: Return on Capital Employed, calculated as the ratio between underlying EBIT (before adjustment for the amortization of PPA) and capital employed. Capital employed consists of net working capital, tangible and intangible assets, goodwill, rights-of-use assets, investments in associates & joint ventures and other investments, and is taken as the average of the situation at the end of the last 4 quarters.

SBTi: Science-based target initiative

SOP: Stock Option Plan.

SPM: The Sustainable Portfolio Management tool is integrated into the Solvay Way framework (linked to five practices). It serves as a strategic tool for developing information on our portfolio and analyzing the impacts of sustainability megatrends on our businesses.

Underlying: Underlying results are deemed to provide a more comparable indication of Solvay's fundamental performance over the reference periods. They are defined as the IFRS figures adjusted for the "Adjustments" as defined above. They provide readers with additional information on the Group's underlying performance over time as well as the financial position and they are consistent with how the business' performance and financial position are reported to the Board of Directors and the Executive Committee.

Underlying Tax rate: Income taxes / (Result before taxes – Earnings from associates & joint ventures – interests & realized foreign exchange results on RusVinyl joint venture) – all determined on an Underlying basis. The adjustment of the denominator regarding associates and joint ventures is made as these contributions are already net of income taxes. This provides an indication of the tax rate across the Group.

Voluntary pension contributions: Contributions to plan assets in excess of Mandatory Contributions to employee benefits plans. These payments are discretionary and are driven by the objective of value creation. These voluntary contributions are excluded from free cash flow as they are deleveraging in nature as a reimbursement of debt.

WACC: Weighted Average Cost of Capital

yoy: Year on year comparison.

Contacts

Investor relations

Jodi Allen +1 609 860 4608

Geoffroy d'Oultremont +32 2 264 29 97

Bisser Alexandrov +32 2 264 36 87

investor.relations@solvay.com

Media relations

Nathalie Van Ypersele +32 478 20 10 62 nathalie.vanypersele@solvay.com

Brian Carroll +32 2 264 15 30 brian.carroll@solvay.com

Peter Boelaert +32 479 30 91 59 peter.boelaert@solvay.com

Safe harbor

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. Solvay undertakes no obligation to publicly update or revise any forward-looking statements.

About Solvay

Solvay is a science company whose technologies bring benefits to many aspects of daily life. With more than 23,000 employees in 64 countries, Solvay bonds people, ideas and elements to reinvent progress. The Group seeks to create sustainable shared value for all, notably through its Solvay One Planet plan crafted around three pillars: protecting the climate, preserving resources and fostering better life. The Group's innovative solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices, health care applications, water and air purification systems. Founded in 1863, Solvay today ranks among the world's top three companies for the vast majority of its activities and delivered net sales of ξ 9.0 billion in 2020. Solvay is listed on Euronext Brussels (SOLB) and Paris and in the United States, where its shares (SOLVY) are traded through a Level I ADR program. Learn more at www.solvay.com.

About Solvay Investor Relations

Results' documentation G.R.O.W. Strategy Share information Credit information ESG information Annual report Webcasts, podcasts and presentations















www.solvay.com/en/investors



Progress beyond